Stephanie Sutton

Sanofi-aventis (Paris) has asked Genzyme to stand aside and let the shareholders decide on whether an acquisition should take place.

Genzyme has outlined why it believes sanofi-aventis?s tender offer of $69 per share "dramatically undervalues the company" and why a price of $89 per share would be more reflective of the company?s true value.

The UK's coalition government has unveiled its spending review and it's good news for the life sciences sector, which has been allocated annual public funding of £4.46 billion ($7 billion) until 2014/2015.

A European pilot initiative will test the impact of consultations with a number of stakeholders such as patient representatives and payers on early stage drug development.

Genzyme has outlined why it believes sanofi-aventis's tender offer of $69 per share "dramatically undervalues the company" and why a price of $89 per share would be more reflective of the company's true value.

A European pilot initiative will test the impact of consultations with a number of stakeholders such as patient representatives and payers on early-stage drug development.

GlaxoSmithKline (GSK) has provided further details concerning its new unit dedicated to rare diseases, which was launched in February.

The European Generic medicines Association (EGA) has made a number of recommendations on how to ensure the quality of medicines in the globalised supply chain; in particular, the EGA spoke about API quality and quality supervision, and how these can be improved by transparent communication between authorities and industry.

The European Generic medicines Association (EGA) has made a number of recommendations on how to ensure the quality of medicines in the globalized supply chain; in particular, the EGA spoke about API quality and quality supervision, and how these can be improved by transparent communication between authorities and industry.

GlaxoSmithKline (GSK) has provided further details concerning its new unit dedicated to rare diseases, which was launched in February.

Following the low growth of the global pharma market in 2010, IMS Health?s IMS Market Prognosis now expects the industry to rebound somewhat in 2011, growing at a rate of 5?7% compared with only 4?5% in 2010 to reach $880 billion.

Restructuring at sanofi-aventis will result in the elimination of approximately 1700 jobs in the US — about 25% of the company?s US Pharmaceutical Operations division workforce.

The European Medicines Agency (EMA) has adopted new policies on access to documents and the handling of conflicts of interest, which should make the processes in these two areas more efficient.

The European Medicines Agency (EMA) has adopted new policies on access to documents and the handling of conflicts of interest

Following the low growth of the global pharmaceutical market in 2010, IMS Health's IMS Market Prognosis now expects the industry to rebound somewhat in 2011, growing at a rate of 5-7%, compared with only 4-5% in 2010, to reach $880 billion.

It?s been a busy few weeks at the European Medicines Agency (EMA), with a number of marketing authorization suspensions and safety reviews launched, including a thorough review of all bisphosphonate-containing medicines following a possible increased risk of atypical stress fractures.

Pharma companies must ensure that patients have access to "objective, unbiased information" about medicines, according to MEPs of the European Parliament?s Health Committee — this should be a patient right rather than an option for pharma companies.

The FDA has issued a final rule that clarifies what safety information must be reported during clinical trials of investigational drugs and biologics.

Pfizer has discontinued a Phase III trial evaluating Sutent (sunitinib malate) in combination with prednisone for men with advanced castration-resistant prostate cancer following disappointing results.

An external review has cleared Elan Corp (Ireland) of any wrongdoing following "a number of matters" brought to the Board?s attention by some directors concerning corporate governance practices.

The EMA and the FDA have extended their confidentiality arrangements for human and veterinary medicinal products following the "positive experience" gained since the initial arrangements were signed in 2003.

The European Medicines Agency (EMA) and the US Food and Drug Administration have extended their confidentiality arrangements for human and veterinary medicinal products.

The European Medicines Agency (EMA) has discussed the possibility of a global framework for clinical trials at an international workshop, given the fact that the majority of clinical trials for medicines approved in Europe are conducted outside of the EMA's regulatory reach.

The European Commission has issued a last call for REACH (Registration, Evaluation, Authorisation and restriction of Chemicals) registration; an EU initiative targeting companies that import or produce chemicals, which will ultimately impact a number of industries, including pharmaceuticals.

After hosting the first international scientific workshop on nanomedicines earlier this month, the European Medicines Agency (EMA) has concluded that further research is needed to provide an adequate scientific basis for evaluating the quality, safety and efficacy of such medicines.

Director General of the European Generic Medicines Association (EGA), Greg Perry, has emphasised the need for EU biosimilar guidelines for monoclonal antibodies (mAbs), as well as a harmonised, global approach to biosimilars in general, at the agency's 8th International Symposium on Biosimilar Medicines.

After hosting the first international scientific workshop on nanomedicines earlier this month, the European Medicines Agency (EMA) has concluded that further research is needed to provide an adequate scientific basis for evaluating the quality, safety, and efficacy of such medicines.

Director General of the European Generic Medicines Association (EGA), Greg Perry, has emphasized the need for EU biosimilar guidelines for monoclonal antibodies (mAbs), as well as a harmonized, global approach to biosimilars in general, at the agency's 8th International Symposium on Biosimilar Medicines.

The European Medicines Agency (EMA) has launched a review of GlaxoSmithKline's pandemic influenza vaccine Pandemrix to investigate whether there is a link between vaccination and cases of narcolepsy, a rare sleep disorder.

GlaxoSmithKline Consumer Healthcare, Cephalon UK Ltd and ProStraken Group plc have been named and publicly shamed for breaching the Association of the British Pharmaceutical Industry's (ABPI) Code of Practice.